This study is testing if a combination of lofexidine and pregabalin can help people manage opioid withdrawal symptoms as outpatients. You could be eligible if you are at least 18 years old, have an opioid use disorder, and are interested in naltrexone (an opioid antagonist treatment). The study aims to see if this drug combination is safe and effective in reducing withdrawal symptoms, measured by your scores on the Subjective Opioid Withdrawal Scale (SOWS) over 10 days. The study is currently unclear on its recruitment status and plans to enroll 150 participants.

Study design

This is a placebo-controlled study where 150 participants will be randomly assigned to receive either lofexidine/pregabalin or lofexidine/placebo pregabalin.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your withdrawal symptoms will be measured for 10 days, through the completion of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.